Biomerica Inc logo

BMRA - Biomerica Inc Share Price

$6.13 -0.1  -2.2%

Last Trade - 26/02/21

Sector
Healthcare
Size
Small Cap
Market Cap £51.8m
Enterprise Value £47.8m
Revenue £4.61m
Position in Universe 5267th / 6715
Bullish
Bearish
Unlock BMRA Revenue
Momentum
Relative Strength (%)
1m -14.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -73.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st May 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
4.96 5.14 5.79 5.56 5.20 6.69 5.97 7.51 +6.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 November 2020, Biomerica, Inc. revenues decreased 10% to $2.5M. Net loss increasedfrom $992K to $3.1M. Revenues reflect Asia segment decreaseof 39% to $897K, Middle East segment decrease of 60% to$125K. Higher net loss reflects Selling, general andadministrative increase from $1.1M to $2.4M (expense),Research and development increase of 63% to $1.3M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BMRA Revenue Unlock BMRA Revenue

Net Income

BMRA Net Income Unlock BMRA Revenue

Normalised EPS

BMRA Normalised EPS Unlock BMRA Revenue

PE Ratio Range

BMRA PE Ratio Range Unlock BMRA Revenue

Dividend Yield Range

BMRA Dividend Yield Range Unlock BMRA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BMRA EPS Forecasts Unlock BMRA Revenue
Profile Summary

Biomerica, Inc. is a biomedical company, which develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The medical diagnostic products are sold in two markets: clinical laboratories and point of care. The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Biomerica has developed a diagnostic guided therapy that is designed to allow physicians to identify patient-specific foods, that when removed from the diet, may alleviate or improve an individual's symptoms of Irritable Bowel Syndrome (IBS). This product is called InFoods IBS.

Directors
Last Annual May 31st, 2020
Last Interim November 30th, 2020
Incorporated September 22, 1971
Public Since March 23, 2009
No. of Shareholders: n/a
No. of Employees: 84
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 11,780,089
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BMRA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BMRA
Upcoming Events for BMRA
Monday 12th April, 2021 Estimate
Q3 2021 Biomerica Inc Earnings Release
Frequently Asked Questions for Biomerica Inc
What is the Biomerica Inc share price?

As of 26/02/21, shares in Biomerica Inc are trading at $6.13, giving the company a market capitalisation of £51.8m. This share price information is delayed by 15 minutes.

How has the Biomerica Inc share price performed this year?

Shares in Biomerica Inc are currently trading at $6.13 and the price has moved by 0.121k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biomerica Inc price has moved by 70.11% over the past year.

What are the analyst and broker recommendations for Biomerica Inc?

Of the analysts with advisory recommendations for Biomerica Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biomerica Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biomerica Inc next release its financial results?

Biomerica Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-11-30
What is the Biomerica Inc dividend yield?

Biomerica Inc does not currently pay a dividend.

Does Biomerica Inc pay a dividend?

Biomerica Inc does not currently pay a dividend.

When does Biomerica Inc next pay dividends?

Biomerica Inc does not currently pay a dividend.

How do I buy Biomerica Inc shares?

To buy shares in Biomerica Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biomerica Inc?

Shares in Biomerica Inc are currently trading at $6.13, giving the company a market capitalisation of £51.8m.

Where are Biomerica Inc shares listed? Where are Biomerica Inc shares listed?

Here are the trading details for Biomerica Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BMRA
What kind of share is Biomerica Inc?

Based on an overall assessment of its quality, value and momentum, Biomerica Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biomerica Inc share price forecast 2021?

Shares in Biomerica Inc are currently priced at $6.13. At that level they are trading at 77.49% discount to the analyst consensus target price of 0.00.

Analysts covering Biomerica Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.42 for the next financial year.

How can I tell whether the Biomerica Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biomerica Inc. Over the past six months, the relative strength of its shares against the market has been -23.97%. At the current price of $6.13, shares in Biomerica Inc are trading at -11.96% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biomerica Inc PE Ratio?

We were not able to find PE ratio data for Biomerica Inc.

Who are the key directors of Biomerica Inc?

Biomerica Inc's management team is headed by:

Zackary Irani - CHM
Francis Cano - IND
Allen Barbieri - VCH
Jane Emerson - IND
Mark Sirgo - IND
Steven Sloan - CFO
Catherine Coste - IND
Who are the major shareholders of Biomerica Inc?

Here are the top five shareholders of Biomerica Inc based on the size of their shareholding:

Irani (Zackary S) Individual Investor
Percentage owned: 8.51% (1.00m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 7.35% (866k shares)
Janet Moore Trust Corporation
Percentage owned: 5.4% (636k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.82% (568k shares)
Granahan Investment Management, Inc. Investment Advisor
Percentage owned: 4.34% (511k shares)
Similar to BMRA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.